Emapalumab, a monoclonal antibody targeting IFN-γ, has been approved to treat primary HLH, a condition with elevated serum levels of IFN-γ.267 Considering the contribution of IFN-γ to CS as mentioned above, emapalumab may be effective in the treatment of COVID-CS. Here, IFNG is linked to hemophagocytic syndrome.